Novonix (NVNXF) Current Deferred Revenue (2020 - 2025)

Novonix has reported Current Deferred Revenue for 6 years, with the latest figure at $146475.0 in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 16.2% year-over-year to $146475.0; the trailing twelve-month figure through Dec 2025 stood at $146475.0 (up 16.2% YoY), and the FY2025 full-year result was $146475.0, up 16.2% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $146475.0, up from $126056.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $285221.0 in Q4 2023, with the low at $2820.7 in Q2 2022.
• Historically, Current Deferred Revenue has averaged $145225.6 across 5 years, with a median of $136265.5 in 2024.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue tumbled 98.82% — and 2023, when it soared 296.22%.
• Novonix's Current Deferred Revenue stood at $238795.6 in 2021, then plunged by 69.85% to $71985.0 in 2022, then soared by 296.22% to $285221.0 in 2023, then plunged by 55.8% to $126056.0 in 2024, then rose by 16.2% to $146475.0 in 2025.
• The last three Current Deferred Revenue figures came in at $146475.0 (Q4 2025), $126056.0 (Q4 2024), and $285221.0 (Q4 2023), per Business Quant data.